APA (7th ed.) Citation

Fujimoto, N., Miyamoto, Y., Wada, S., Hotta, K., Kozuki, T., Aoe, K., . . . Harada, D. (2021). JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Fujimoto, Nobukazu, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, and Daijiro Harada. JME-001 Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma. BMJ Publishing Group, 2021.

MLA (8th ed.) Citation

Fujimoto, Nobukazu, et al. JME-001 Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma. BMJ Publishing Group, 2021.